Govt Approves 1st Use Of Regenerative Medicine In Japan (Japan)
This article was originally published in PharmAsia News
The Japanese government has given approval to Bioventure Japan Tissue Engineering Co. (J-TEC) to manufacture and sell skin for use in treating serious burns, the first such approval for the use of regenerative medicine in Japan. Skin cells that have been cultured for approximately two weeks are used in the treatment, with technology enabling a 1-sq.-cm sample to grow up to 1,000 times larger. The new skin, once grown, is applied to the damaged part of the body, significantly reducing the chances of rejection compared with procedures using another person's skin. J-TEC also plans to seek approval from the Health Ministry for regenerative treatments to restore the functions of knee cartilage and the epithelium of the cornea. (Click here for more - May Require Paid Subscription
You may also be interested in...
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.
One pilot target domestic manufacturers of finished drugs and another foreign manufacturers of APIs. As an incentive to participate, companies assigned high scores will be accorded regulatory flexibility. Also, participants that disclose facility ratings could “benefit from a competitive advantage.”